Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Michigan: - Hickman Cancer Center — Adrian, Michigan
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Michigan: - Hickman Cancer Center — Adrian, Michigan
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in Michigan: - Saint Joseph Mercy Hospital — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Saint Joseph Mercy Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Saint Joseph Mercy Canton — Canton, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion — Detroit, Michigan
- Cancer And Hematology Centers of Western Michigan PC — Grand Rapids, Michigan
- Henry Ford Providence Novi Hospital — Novi, Michigan
- Henry Ford Providence Southfield CK Potluri Cancer Center — Southfield, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
- Henry Ford Hospital — Detroit, Michigan
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
- Corewell Health - Lemmen-Holton Cancer Pavilion — Grand Rapids, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
- Henry Ford Cancer Institute — Detroit, Michigan
- Henry Ford Health Providence Southfield Hospital — Southfield, Michigan
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Michigan: - Regents of the University of Michigan /ID# 261577 — Ann Arbor, Michigan
- Karmanos Cancer Institute - Detroit /ID# 266298 — Detroit, Michigan
- Henry Ford Hospital /ID# 262704 — Detroit, Michigan
- Barbara Ann Karmanos Cancer Institute - McLaren Greater Lansing /ID# 259891 — Lansing, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in Michigan: - University of Michigan - Rogel Cancer Center — Ann Arbor, Michigan
- Henry Ford Health System - The Henry Ford Cancer Institute (HFCI) - Detroit — Detroit, Michigan
- Cancer & Hematology Centers of Western Michigan (CHCWM) — Grand Rapids, Michigan
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in Michigan: - Research Site — Detroit, Michigan
Phase 3 Recruiting Industry
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Sponsor: GlaxoSmithKline
NCT ID: NCT06679101
Sites in Michigan: - GSK Investigational Site — Ann Arbor, Michigan
Phase 3 Recruiting Industry
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multip…
Sponsor: Takeda
NCT ID: NCT06980480
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05438043
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Michigan: - Trinity Health Ann Arbor Hospital — Ann Arbor, Michigan
- University of Michigan — Ann Arbor, Michigan
- Henry Ford Health Saint John Hospital — Detroit, Michigan
- Genesys Hurley Cancer Institute — Flint, Michigan
- Cancer Research Consortium of West Michigan — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Sponsor: AstraZeneca
NCT ID: NCT05850234
Sites in Michigan: - Research Site — Ann Arbor, Michigan
- Research Site — Detroit, Michigan
Phase 2 Recruiting Industry
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…
Sponsor: Sanofi
NCT ID: NCT06356571
Sites in Michigan: - Michigan Hematology & Oncology Consultants - Dearborn- Site Number : 8400036 — Dearborn, Michigan
- Hematology Oncology Consultants - Royal Oak- Site Number : 8400039 — Royal Oak, Michigan
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively trea…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03761108
Sites in Michigan: - C. S. Mott_University of Michigan — Ann Arbor, Michigan
- Barbara Ann Karmanos Cancer Center — Detroit, Michigan
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT04634552
Sites in Michigan: - University of Michigan Health System — Ann Arbor, Michigan
Phase 2 Recruiting Network
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be a…
Sponsor: Multiple Myeloma Research Consortium
NCT ID: NCT06171685
Sites in Michigan: - Barbara Ann Karmanos Cancer Center — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem c…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05828511
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants …
Sponsor: AstraZeneca
NCT ID: NCT06106945
Sites in Michigan: - Research Site — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06292780
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 2 Recruiting Industry
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06140524
Sites in Michigan: - University of Michigan Health — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of ABBV-453 in adult participants with r…
Sponsor: AbbVie
NCT ID: NCT06953960
Sites in Michigan: - University of Michigan Health System - Ann Arbor /ID# 271536 — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 …
Sponsor: Sanofi
NCT ID: NCT04643002
Sites in Michigan: - University of Michigan Health System - Ann Arbor- Site Number : 8400004 — Ann Arbor, Michigan